CTI Clinical Trial and Consulting Services Announces the Formation of Italian Subsidiary and Opens Office in Milan, Italy
CTI Clinical Trial and Consulting Services (CTI) announces that it has opened an office in Milan, Italy. The office is opened through its newly created wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Italy, S.R.L.
CTI Clinical Trial and Consulting Services
(CTI) announces that it has opened an office in Milan, Italy. The office is opened through its newly created wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Italy, S.R.L.
“We believe that the market for clinical research is continuing its growth throughout Europe, and Italy is a key location,” states Patrick Earley, General Manager at CTI. “Milan has a very dynamic economy, serving as a hub for the Italian pharmaceutical and biotechnology industries, which makes it ideal for a new location. We have had ongoing relationships with many key Italian research leaders for several years, and this expansion will allow us to continue to enhance our collaborations.”
CTI has been working for nearly fifteen years in the drug development industry in North America, Europe, and South America, specializing in clinical research programs involving critically ill patient populations. The office in Italy is the seventh CTI office in Europe and the second European office to open in 2013.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
